Global Information
회사소개 | 문의 | 위시리스트

루게릭병(ALS) : 역학 예측(-2027년)

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

리서치사 GlobalData
발행일 2018년 07월 상품 코드 682050
페이지 정보 영문 32 Pages
가격
US $ 3,995 ₩ 4,773,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,547,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 14,320,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


루게릭병(ALS) : 역학 예측(-2027년) Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027
발행일 : 2018년 07월 페이지 정보 : 영문 32 Pages

세계 주요 7개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 루게릭병(ALS : Amyotrophic Lateral Sclerosis)에 대해 조사 분석했으며, 질환 배경, 위험인자와 병존 질환, 세계의 동향, 역학 예측 등의 정보를 전해드립니다.

제1장 목차

제2장 주요 요약

제3장 역학

  • 질환 배경
  • 위험인자와 병존 질환
  • 세계의 동향과 과거 동향
    • 미국
    • EU 5개국
    • 일본
  • 예측 방법
    • 정보 출처
    • 예측 가정과 조사 방법
  • ALS의 역학 예측
    • ALS로 진단된 환자 총수
    • ALS의 총환자수(연령별)
    • ALS의 총환자수(성별)
    • ALS로 진단된 환자수 : 종류별
    • ALS 환자 총수
  • 논의
    • 역학 예측에 관한 분석
    • 분석의 한계
    • 분석의 강점

제4장 부록

KSM 18.09.03

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for ALS 7
  • Table 2: High-Prescribing Physicians (Non-Key Opinion Leaders) Surveyed, By Country 28

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2017 and 2027 5
  • Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of ALS, Ages ≥40 Years, 2017 9
  • Figure 3:Sources Used for Diagnosed Prevalent Cases of ALS 11
  • Figure 4:Sources Used for Diagnosed Prevalent Cases of ALS Type 12
  • Figure 5: 7MM, Diagnosed Prevalent Cases of ALS, Men and Women, Ages ≥40 Years, 2017 18
  • Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of ALS, Men and Women, 2017 19
  • Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of ALS, Men and Women, Ages ≥40 Years, 2017 20
  • Figure 8: 7MM, Diagnosed Prevalent Cases of ALS by Type, Men and Women, Ages ≥40 Years, 2017 21
  • Figure 9: 7MM, Total Prevalent Cases of ALS, Men and Women, Ages ≥40 Years, 2017 22

Amyotrophic Lateral Sclerosis (ALS) is often referred to as "Lou Gehrig's Disease" after the famous baseball player who was diagnosed with the disease in 1939. Amyotrophic Lateral Sclerosis (ALS) is a rare but fatal progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. Amyotrophic Lateral Sclerosis (ALS) severely impacts physical functioning, and initially presents with muscle twitching, weakness in an arm or leg, or sometimes with slurring of speech. Eventually, people with Amyotrophic Lateral Sclerosis (ALS) lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death.

In 2017, the 7MM had 46,240 diagnosed prevalent cases of Amyotrophic Lateral Sclerosis (ALS). This is expected to increase to 52,712 diagnosed prevalent cases by 2027, at an Annual Growth Rate (AGR) of 1.40%. The increase is driven by the aging population in the 7MM. In 2017, the 7MM had 53,024 total prevalent cases of Amyotrophic Lateral Sclerosis (ALS). This is expected to increase to 60,304 total prevalent cases by 2027, at an AGR of 1.37%. The US had the highest number of diagnosed prevalent and total prevalent cases of Amyotrophic Lateral Sclerosis (ALS).

Epidemiologist forecasts that all markets will see an increase in the diagnosed prevalent cases of Amyotrophic Lateral Sclerosis (ALS)during the forecast period. However, the development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

The report "Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027", provides an overview of the risk factors, comorbidities, and the global and historical trends for Amyotrophic Lateral Sclerosis (ALS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of Amyotrophic Lateral Sclerosis (ALS).

Scope

  • The Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast Report provides an overview of the risk factors and global trends of ALS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 40 years and older across the 7MM: 10-year epidemiological forecast for the total (medically diagnosed and undiagnosed) and diagnosed prevalent cases of ALS. The diagnosed prevalent cases are further segmented by age (40 years and older), sex, and type of ALS based on sporadic and familial component.
  • The ALS epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The ALS Epidemiology Forecast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global ALS market.
  • Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ALS therapeutics in each of the markets covered.
  • Understand proportion of ALS population based on sporadic and familial component.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Amyotrophic Lateral Sclerosis: Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Reports 5

3 Epidemiology 6

  • 3.1 Disease Background 6
  • 3.2 Risk Factors and Comorbidities 6
  • 3.3 Global and Historical Trends 7
    • 3.3.1 US 9
    • 3.3.2 5EU 9
    • 3.3.3 Japan 10
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 11
    • 3.4.2 Forecast Assumptions and Methods 13
  • 3.5 Epidemiological Forecast for ALS (2017-2027) 17
    • 3.5.1 Diagnosed Prevalent Cases of ALS 17
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of ALS 19
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of ALS 20
    • 3.5.4 Diagnosed Prevalent Cases of ALS by Type 21
    • 3.5.5 Total Prevalent Cases of ALS 22
  • 3.6 Discussion 23
    • 3.6.1 Epidemiological Forecast Insight 23
    • 3.6.2 Limitations of Analysis 24
    • 3.6.3 Strengths of Analysis 25

4 Appendix 26

  • 4.1 Primary Research - Prescriber Survey 28
  • 4.2 About the Authors 29
    • 4.2.1 Epidemiologist 29
    • 4.2.2 Reviewers 29
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 30
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 30
  • 4.3 About GlobalData 31
  • 4.4 Contact Us 31
  • 4.5 Disclaimer 31
Back to Top
전화 문의
F A Q